Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.

Elisabeth Bergen,Amelie Binter,Angelika M. Starzer,Gerwin Heller,Barbara Kiesel,Kristina Tendl-Schulz,Zsuzsanna Bago-Horvath,Julia Furtner,Johannes Leitner,Ruth Exner,Florian Fitzal,Karin Dieckmann,Georg Widhalm,Matthias Preusser,Anna S. Berghoff,Rupert Bartsch

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab.

2021

Elisabeth Bergen
Amelie Binter
Angelika M. Starzer
Gerwin Heller
Barbara Kiesel
Kristina Tendl-Schulz
Zsuzsanna Bago-Horvath
Julia Furtner
Johannes Leitner
Ruth Exner
Florian Fitzal
Karin Dieckmann
Georg Widhalm
Matthias Preusser
Anna S. Berghoff
Rupert Bartsch

Background:Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab (TP) is a standard therapy of metastatic and localized HER2-positive breast cancer (BC), but...

Keywords:

Oncology
Blockade
Trastuzumab
Breast cancer
standard therapy
dual blockade
Human Epidermal Growth Factor Receptor 2
Medicine
Pertuzumab
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations